Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
601-620 of 1,307 trials

Atopic Dermatitis in Children: Abrocitinib Study

We are investigating the effectiveness and safety of Abrocitinib for children aged 6 to under 12 with moderate-to-severe atopic dermatitis. The study will compare it to a placebo while using other topical treatments.

Moderate-to-Severe Atopic Dermatitis3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Pulmonary Arterial Hypertension: Sotatercept Study

We are evaluating the long-term safety of sotatercept for adults with pulmonary arterial hypertension already on treatment. This study will help us understand how well it works when added to existing therapies.

Pulmonary Arterial Hypertension>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiology

Fecal Microbiome Transplantation for Decompensated Cirrhosis

We are studying whether fecal microbiome transplantation can help slow the progression of decompensated cirrhosis in patients. The trial will assess its effects on survival, complications, and overall health.

Decompensated Cirrhosis1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesGastroenterologyHepatology

Sickle Cell Disease: Etavopivat Treatment Study

We are evaluating how well etavopivat works for adolescents and adults with sickle cell disease. The study aims to see if it improves symptoms and quality of life compared to a placebo.

Sickle Cell Disease>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Hand Osteoarthritis: Metformin Treatment

We are investigating whether metformin can reduce finger joint pain in people with hand osteoarthritis. This study compares its effects to a placebo over 16 weeks.

Hand Osteoarthritis3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineRheumatology

Thyroid Eye Disease: Efgartigimod PH20 SC

We are studying a new treatment for adults with thyroid eye disease to see if it reduces eye bulging compared to a placebo. This trial will help us understand its effectiveness and safety.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology

Thyroid Eye Disease: Efgartigimod PH20 SC Study

We are testing a new treatment called efgartigimod PH20 SC in adults with thyroid eye disease. The goal is to see if it works better than a placebo in reducing symptoms.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology

MOG Antibody-Associated Disease: Rozanolixizumab Study

We are studying whether Rozanolixizumab is effective and safe for adults with MOG antibody-associated disease. This research aims to provide insights into a potential new treatment for this condition.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurology

Ulcerative Colitis in Kids: Ozanimod Study

We are testing the oral medication ozanimod in children with moderately to severely active ulcerative colitis who haven't responded to other treatments. The goal is to see if it helps improve their symptoms and overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Relapsing Multiple Sclerosis: Remibrutinib vs. Ocrelizumab

We are studying whether remibrutinib is as effective and safe as ocrelizumab for people with relapsing multiple sclerosis after switching treatments. This trial will help us understand the best options for managing the disease.

Relapsing Multiple SclerosisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNeurology

Pulmonary Arterial Hypertension: Ralinepag Study

We are studying the long-term safety and effects of ralinepag in patients with pulmonary arterial hypertension. This trial aims to see how it impacts walking ability, heart health, and overall quality of life.

Pulmonary HypertensionConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyPulmonology

Complement 3 Glomerulopathy: Study of Iptacopan

We are evaluating the safety and effectiveness of iptacopan for patients with complement 3 glomerulopathy. The study aims to see if it can reduce protein levels in urine and improve kidney function.

C3 Glomerulopathy1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNephrology

Gastro-Enteropancreatic Neuroendocrine Tumors: RYZ101 Treatment

We are studying a new treatment, RYZ101, for patients with advanced GEP-NETs that have progressed after previous therapy. The trial compares RYZ101 to standard care to see if it improves patient outcomes.

Gastroenteropancreatic Neuroendocrine TumorsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

C3 Glomerulopathy: Iptacopan Study

We are studying the long-term safety and effectiveness of iptacopan for individuals with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis. This research aims to understand how well the treatment works in improving kidney health.

C3 Glomerulopathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Relapsing Multiple Sclerosis: Remibrutinib vs. Teriflunomide

We are studying whether remibrutinib is more effective than teriflunomide in reducing relapses for individuals with relapsing multiple sclerosis. The trial also examines the safety and impact of both treatments on daily life.

Relapsing Multiple Sclerosis>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteNeurology

Systemic Sclerosis-Related Lung Disease: Belimumab Study

We are investigating the long-term safety and effects of belimumab in adults with lung disease linked to systemic sclerosis. This study aims to see how the treatment impacts lung function and overall tolerability.

Lung Involvement in Systemic SclerosisBronchial Diseases>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPulmonologyRheumatology

Crohn's Disease: Vedolizumab with Upadacitinib

We are studying whether a combination of vedolizumab and upadacitinib helps improve symptoms in adults with moderately to severely active Crohn's disease compared to vedolizumab alone.

Crohn's Disease>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

HIV-1 Treatment: Bictegravir/Lenacapavir for Kids and Teens

We are studying a new combination medication for children and adolescents with HIV-1 to see how well it works and how safe it is. The trial will also check if young patients find the medication easy to take.

HIV-1 Infection6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Preventing Opioid-Induced Constipation in Advanced Cancer Patients

We are comparing two laxatives to see which one better prevents constipation in patients with advanced cancer starting opioid pain treatment. This study will also assess quality of life and side effects.

Advanced Cancer≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOncology

ILUVIEN® Eye Implant for Children with Uveitis

We are studying the safety and effectiveness of the ILUVIEN® eye implant in children aged 6 to under 18 with recurrent non-infectious uveitis. This research aims to understand how well the implant works and any possible side effects.

Posterior Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementOphthalmologyPediatrics